Hercent
Generic Name
Trastuzumab
Manufacturer
Aurobindo Pharma (hypothetical for this specific brand/form)
Country
India
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| hercent 40 mg tablet | ৳ 120.00 | ৳ 1,200.00 |
Description
Overview of the medicine
Trastuzumab is a monoclonal antibody used to treat HER2-positive breast cancer, metastatic gastric cancer, and gastroesophageal junction adenocarcinoma. Hercent-40-mg-tablet is a hypothetical oral formulation of Trastuzumab, as the standard formulation is intravenous.
Uses & Indications
Dosage
Adults
Hypothetically, 40 mg orally once daily. Dosing should be determined by an oncologist based on individual patient characteristics, disease stage, and tolerability. Not a standard dosing regimen as Trastuzumab is typically IV.
Elderly
No specific dose adjustment required based on age for Trastuzumab, but monitor for adverse effects, especially cardiac, in elderly patients.
Renal_impairment
No specific dose adjustment recommended for Trastuzumab; however, monitor patients closely.
How to Take
Take the tablet orally with water, with or without food, as directed by your oncologist. Do not crush, chew, or split the tablet. Swallow whole.
Mechanism of Action
Binds specifically to the extracellular domain of the HER2 protein, inhibiting cell proliferation and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
Pharmacokinetics
Onset
Weeks to months for full therapeutic effect, given the chronic nature of cancer therapy. Not an acute onset agent.
Excretion
Elimination primarily through catabolism; renal elimination is minimal.
Half life
Approximately 28 days (for the IV formulation, assuming systemic absorption for oral is achieved).
Absorption
For a hypothetical oral tablet, systemic absorption would be variable and likely limited due to the protein nature of Trastuzumab and potential proteolytic degradation in the GI tract. (IV formulation: complete bioavailability)
Metabolism
Catabolized into smaller peptides and amino acids via general protein catabolism; not metabolized by cytochrome P450 enzymes.
Side Effects
Contraindications
- Known hypersensitivity to Trastuzumab, mouse proteins, or any excipients of Hercent-40-mg-tablet
- Severe cardiac dysfunction (e.g., uncontrolled heart failure, recent myocardial infarction)
Drug Interactions
Taxanes
May affect Trastuzumab pharmacokinetics, but often co-administered with careful monitoring.
Anthracycline-containing regimens
Increased risk of cardiac dysfunction.
HER2-targeted tyrosine kinase inhibitors (e.g., Lapatinib)
May enhance efficacy or toxicity, careful consideration needed.
Storage
Store at controlled room temperature (20-25°C), excursions permitted to 15-30°C. Protect from moisture and direct light. Keep out of reach of children.
Overdose
No specific antidote for Trastuzumab overdose. Management should involve supportive care and close monitoring for adverse reactions, especially cardiac and pulmonary complications. Discontinue or interrupt treatment as necessary.
Pregnancy & Lactation
Pregnancy Category D. May cause oligohydramnios, renal dysfunction, and fetal death. Women of reproductive potential should use effective contraception during treatment and for 7 months after the last dose. Not recommended during lactation due to potential for serious adverse reactions in breastfed infants.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the manufacturing date. Refer to the specific product packaging for exact expiry details.
Availability
Hospitals, oncology clinics, specialized pharmacies
Approval Status
Approved by regulatory bodies for various HER2-positive cancers (original IV formulation)
Patent Status
Original molecule patent expired, biosimilars available
WHO Essential Medicine
YesClinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of intravenous Trastuzumab. Specific clinical trials for an oral Trastuzumab formulation would be required to establish its safety and efficacy, and may be ongoing or hypothetical.
Lab Monitoring
- Left Ventricular Ejection Fraction (LVEF) using echocardiogram or MUGA scan (baseline and periodically during treatment, typically every 3 months)
- Complete Blood Count (CBC) with differential
- Liver function tests (LFTs)
Doctor Notes
- Prioritize comprehensive cardiac assessment (LVEF) before initiating and periodically during Trastuzumab treatment.
- Counsel patients thoroughly regarding the risk of cardiac toxicity and signs of heart failure.
- Emphasize strict adherence to contraception guidelines for female patients of reproductive age.
- Regularly monitor for pulmonary symptoms and signs of severe hypersensitivity reactions.
Patient Guidelines
- Report any signs or symptoms of heart failure (e.g., shortness of breath, cough, swelling of ankles/legs) immediately.
- Do not stop taking Hercent-40-mg-tablet without consulting your oncologist.
- Attend all scheduled follow-up appointments, including cardiac monitoring tests.
- Use effective contraception during treatment and for 7 months after the last dose.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one. Contact your doctor for advice.
Driving Precautions
Hercent-40-mg-tablet may cause fatigue, dizziness, or vision disturbances. Patients should exercise caution when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Maintain a heart-healthy lifestyle, including a balanced diet and regular, moderate exercise, if able.
- Avoid excessive alcohol consumption.
- Quit smoking to reduce cardiovascular risks and improve overall health outcomes.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.